Oxford University Press, Open Forum Infectious Diseases, 2024
DOI: 10.1093/ofid/ofae158
Full text: Unavailable
Abstract 15% of solid organ transplant recipients on belatacept developed invasive fungal diseases (IFD). The most common IFD were aspergillosis (56%) and candidiasis (22%). The infected cohort was more likely to receive basiliximab, lung transplantation, or identify as White. Higher rates of aspergillosis were seen in this lung cohort than previously reported.